LEQEMBI IQLIK® Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK® Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
FDA Approves LEQEMBI IQLIK® Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® 2026
Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol Phase 3 Study Results in Systemic Lupus Erythematosus
Topline Results from Phase 2 CELIA Study of Diranersen : First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease
DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
